Alpha Tau Medical (DRTS) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Tau Medical (DRTS) has outperformed Oric Pharmaceuticals (ORIC) over the past year, gaining 245.0% versus a loss of 14.9%. Over five years, DRTS leads with a +44.1% price change compared with -26.0% for ORIC. Alpha Tau Medical is the larger company by market cap ($1.32 billion vs $1.24 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRTS | ORIC |
|---|---|---|
| Share price | $14.25 | $12.01 |
| Market cap | $1.32B | $1.24B |
| 1-day change | -1.59% | +0.25% |
| YTD return | +187.88% | +46.82% |
| 1-year return | +245.04% | -14.94% |
| 5-year return | +44.08% | -26.00% |
| EPS (TTM) | $-1.04 | $-1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.79 | $14.68 |
| 52-week low | $3.43 | $7.23 |
| Distance from 52-week high | -9.75% | -18.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +24.91% | +78.43% |
| Average volume | 568.24K | 1.47M |
| Shares outstanding | 92.48M | 103.65M |
| Employees | 121 | 111 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRTS has outperformed ORIC by 260.0 percentage points over the past year.
About Alpha Tau Medical
DRTS stock →Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Health Care · Medical/Dental Instruments · 121 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
DRTS vs ORIC FAQ
Which is bigger, Alpha Tau Medical or Oric Pharmaceuticals?
Alpha Tau Medical (DRTS) is larger, with a market capitalization of $1.32B compared with $1.24B for Oric Pharmaceuticals (ORIC).
Which stock has performed better over the past year, DRTS or ORIC?
DRTS returned +245.04% over the past 12 months, compared with -14.94% for ORIC (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Tau Medical and Oric Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Alpha Tau Medical and Biotechnology: Pharmaceutical Preparations for Oric Pharmaceuticals.